On August 27th, it was reported in the market that due to efficacy issues, Sanofi has decided to temporarily suspend the supply and sale of influenza vaccines in China.
Regarding this, a reporter from Nancai Express called Sanofi, and the customer service representative responded, "There is currently no definite news and we need to wait for an official response
Flu vaccine concept stocks in the secondary market also experienced fluctuations, with Hualan Vaccine (301207. SZ) and Jindike (688670. SH) both hitting the daily limit up of 20CM in the morning, while Baike Biotechnology (688276. SH) and others followed suit.
The reporter called Hualan Vaccine as an investor, and relevant personnel stated that there is no potency issue with the company's influenza vaccine. If Sanofi withdraws from the supply, there will be no products from the company during this year's vaccination season, which is a good thing for other competing manufacturers. As for how much specific share each company can receive, it cannot be predicted.
In addition, the reporter also called Jindick multiple times, but was unable to get through.
(Disclaimer: The content of this article is for reference only and does not constitute investment advice. Investors operate based on this and bear the risks themselves.)